Drug Mechanism Clinical Trial
— PSKOfficial title:
Kit de Pharmacologie Spatial - Analyse de l'Utilisation Des Dried Blood Spot Pour le Dosage de la caféine Chez Des Volontaires Sains en microgravité au Cours Des Vols Paraboliques
Verified date | May 2024 |
Source | Institut National de la Santé Et de la Recherche Médicale, France |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The PSK study is preliminary to the study of drug metabolism in space flight conditions. The investigators propose to use simplified blood sampling methods that can be applied in microgravity. This method is based on the use of capillary blood, obtained using an automatic lancet for diabetics, the blood droplet then being deposited on specific blotting paper, and then studied in the laboratory. In 2022, the investigators validated the transfer of artificial blood in parabolic flight conditions, as well as the validity of cardiovascular drug dosage. The objective of the 2023 study is to validate the collection and transfer of capillary blood, on themselves, by healthy volunteers with little training, for the blood dosage of caffeine after intake of standard doses of alimentary caffeine. The primary objective is a feasibility of 90% of sampling in microgravity, compared with 95% on ground. Secondary objectives are the pharmacokinetic of different forms of caffeine, according to genetic background and other modifiers of CYP1A2.
Status | Completed |
Enrollment | 30 |
Est. completion date | April 3, 2024 |
Est. primary completion date | April 3, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Be affiliated to a social security scheme or benefit from such a scheme. - Have obtained a medical certificate stating that they are fit for parabolic flights. - Be aged between 18 and 70 - Be in good health: no chronic treatment that could interact with the metabolism of caffeine, no progressive disease - Must not have any contraindications to taking caffeine (30 to 100 mg). Volunteers will also be asked not to consume caffeine (coffee, chocolate, energy drinks, tea, cola, etc.) in the 24 hours preceding the experiment. Exclusion Criteria: - Be the subject of a legal protection measure (safeguard of justice, curatorship or guardianship) - suffer from haematophobia (irrational fear of blood) - Have a current infectious disease, particularly viral - Have an active chronic illness - Have a high usual intake of caffeine (>4 espressos, >4 cups of tea, >100g dark chocolate per day) - Total intolerance to all forms of caffeine - Smoke more than 20 cigarettes a day - Have weaned themselves off smoking for less than a month - Have a history of severe Raynaud's phenomenon - Have a history of naupathy - Suffering from naupathy during a flight |
Country | Name | City | State |
---|---|---|---|
France | AIRBUS A 310 - Zero-G | Mérignac |
Lead Sponsor | Collaborator |
---|---|
Institut National de la Santé Et de la Recherche Médicale, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of valid capillary blood deposit on dry support | A blood transfer is considered as successful IF the 3 following criteria are fulfilled
Blood spot covering > 8 mm2 (3 mm punch circle) Obtaining a drop of blood within the allotted time of 22 sec of microgravity The drop is neither smeared nor smashed on the blotting paper |
through study completion, an average of 3 days | |
Secondary | Identification of factors leading to self-sampling failure a. Time too short b. Insufficient drop c. Inadequate transfer | Identification of self-sampling failure factors
Deposition time in flight > 22 seconds of weightlessness Blood stain covering 80% or more of the reference circle: diameter of the stain taken by photography |
through study completion, an average of 1 year | |
Secondary | Caffeine kinetic under different formulations and dosages | Area under the curve of caffeine and paraxanthine, metabolic ratio (para/caffeine) | through study completion, an average of 3 days | |
Secondary | Caffeine kinetic under different CYP1A2 genotypes | Area under the curve of caffeine and paraxanthine, metabolic ratio (para/caffeine) | through study completion, an average of 3 days | |
Secondary | Caffeine kinetic under different gravity conditions | Area under the curve of caffeine and paraxanthine, metabolic ratio (para/caffeine) | through study completion, an average of 3 days | |
Secondary | Acceptability | A paper questionnaire will be handed out just after the parabolic flight at the time of the last sampling. It will be made up of closed questions based on 3 dimensions of satisfaction:
The quality of the information given by the investigating team on the capillary blood sampling process in order to improve our paper-based operating procedure. Their physical and psychological well-being during the finger prick test demonstration phase before the flight, during the flight and at the end of the flight campaign to ensure that the participants felt comfortable and confident in the sampling situation. Assessment of their performance during the study in flight and on the ground, and whether they would be interested in self-sampling for a future space mission. |
through study completion, an average of 1 year | |
Secondary | Stability of dry blood spots | Area under the curve of caffeine and paraxanthin, metabolic ratio (para/caffeine) at 6 months interval
Visual appearance (degradation, colour change, etc.) Comparison of relative areas obtained during the study with those obtained in a conventional laboratory situation |
through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04659343 -
TDM for Optimized Outcome in Patients With mRCC.
|
||
Recruiting |
NCT01565759 -
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects
|
Phase 1 | |
Completed |
NCT02458261 -
Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Continuous Renal Replacement Therapy
|
||
Completed |
NCT01963130 -
Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study
|
N/A | |
Completed |
NCT04690673 -
Detection of Paracetamol Concentration in Blood-, Saline- and Urine Samples - a Validation Study for a Novel Technique
|
N/A | |
Recruiting |
NCT05212389 -
The Pill Project - Oral Contraceptive and Serotonergic Brain Signaling
|
N/A |